Patients who rush escalation often end up taking breaks or reducing doses to manage side effects, ultimately delaying progress more than the standard protocol would
[1] [3] It is essential to understand that retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) , which is the body responsible for licensing medicines for use in the UK following the UK's departure from the European Union
Ishii M, Shimizu S, Nawata S, et al
Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others approximately 14 of the original 19 restricted compounds